Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Outpatient thromboprophylaxis with low-molecular-weight heparin in solid tumors: Where do we stand today?

Literature DB >> 26931102

Outpatient thromboprophylaxis with low-molecular-weight heparin in solid tumors: Where do we stand today?

Thein Hlaing Oo¹.

Abstract

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2016 PMID： 26931102 DOI： 10.1007/s11239-016-1346-3

Source DB: PubMed Journal: J Thromb Thrombolysis ISSN： 0929-5305 Impact factor: 2.300

× No keyword cloud information.

11 in total

1. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.

Authors: Alessandra Larocca; Federica Cavallo; Sara Bringhen; Francesco Di Raimondo; Anna Falanga; Andrea Evangelista; Maide Cavalli; Anfisa Stanevsky; Paolo Corradini; Sara Pezzatti; Francesca Patriarca; Michele Cavo; Jacopo Peccatori; Lucio Catalano; Angelo Michele Carella; Anna Maria Cafro; Agostina Siniscalchi; Claudia Crippa; Maria Teresa Petrucci; Dina Ben Yehuda; Eloise Beggiato; Tommaso Caravita Di Toritto; Mario Boccadoro; Arnon Nagler; Antonio Palumbo
Journal: Blood Date: 2011-08-11 Impact factor: 22.113

2. Reply to M.G. McNamara et al and T.H. Oo.

Authors: Uwe Pelzer; Hanno Riess
Journal: J Clin Oncol Date: 2016-01-04 Impact factor: 44.544

3. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.

Authors: Antonio Palumbo; Michele Cavo; Sara Bringhen; Elena Zamagni; Alessandra Romano; Francesca Patriarca; Davide Rossi; Fabiana Gentilini; Claudia Crippa; Monica Galli; Chiara Nozzoli; Roberto Ria; Roberto Marasca; Vittorio Montefusco; Luca Baldini; Francesca Elice; Vincenzo Callea; Stefano Pulini; Angelo M Carella; Renato Zambello; Giulia Benevolo; Valeria Magarotto; Paola Tacchetti; Norbert Pescosta; Claudia Cellini; Claudia Polloni; Andrea Evangelista; Tommaso Caravita; Fortunato Morabito; Massimo Offidani; Patrizia Tosi; Mario Boccadoro
Journal: J Clin Oncol Date: 2011-01-31 Impact factor: 44.544

4. Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial.

Authors: Alok A Khorana; Charles W Francis; Nicole M Kuderer; Marc Carrier; Thomas L Ortel; Ted Wun; Deborah Rubens; Susan Hobbs; Renuka Iyer; Derick Peterson; Andrea Baran; Katherine Kaproth-Joslin; Gary H Lyman
Journal: Thromb Res Date: 2017-01-26 Impact factor: 3.944

5. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer.

Authors: A Maraveyas; J Waters; R Roy; D Fyfe; D Propper; F Lofts; J Sgouros; E Gardiner; K Wedgwood; C Ettelaie; G Bozas
Journal: Eur J Cancer Date: 2011-11-17 Impact factor: 9.162

6. Efficacy of Prophylactic Low-Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial.

Authors: Uwe Pelzer; Bernhard Opitz; Gerd Deutschinoff; Martina Stauch; Peter C Reitzig; Sabine Hahnfeld; Lothar Müller; Martina Grunewald; Jens M Stieler; Marianne Sinn; Timm Denecke; Sven Bischoff; Helmut Oettle; Bernd Dörken; Hanno Riess
Journal: J Clin Oncol Date: 2015-05-18 Impact factor: 44.544

Outpatient thromboprophylaxis with low-molecular-weight heparin in solid tumors: Where do we stand today?

1. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.

2. Reply to M.G. McNamara et al and T.H. Oo.

3. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.

4. Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial.

5. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer.

6. Efficacy of Prophylactic Low-Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial.

7. Prediction of venous thromboembolism in cancer patients.

8. Screening high-risk cancer patients for VTE: a prospective observational study.

Review 9. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.

Review 10. Guidance for the prevention and treatment of cancer-associated venous thromboembolism.

Review 1. Venous thromboembolism prophylaxis for ambulatory cancer patients, can we do better?